Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Jackson

Endocrinology, Diabetes & Metabolism Bridgeport, WV Medical Doctor

NPI 1255444766 CMS profile 192716

710 Genesis Blvd, Bridgeport, WV 26330

Open in the dashboard

General payments

$7,107

397 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Jackson of Bridgeport, WV is reported in the CMS Open Payments database as having received $7,107 across 397 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $25 1
2023 General $16 1
2022 General $2,489 135
2021 General $2,791 153
2020 General $1,472 91
2019 General $314 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Jackson
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Timothy Jackson were reported at $25. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Timothy Jackson Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $314 $494 $123–$2,253 $163
2020 $1,472 $335 $85–$1,841 $114
2021 $2,791 $398 $88–$1,981 $132
2022 $2,489 $364 $88–$1,568 $149
2023 $16 $420 $113–$1,614 $160
2024 $0 $440 $121–$1,646 $164
2025 $25 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,560 91 payments
  2. AstraZeneca Pharmaceuticals LP $761 51 payments
  3. Lilly USA, LLC $694 37 payments
  4. Dexcom, Inc. $661 26 payments
  5. Sanofi-Aventis U.S. LLC $604 36 payments
  6. Abbott Laboratories $544 33 payments
  7. Amgen Inc. $533 25 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $255 17 payments
  9. Merck Sharp & Dohme Corporation $158 11 payments
  10. Mannkind Corporation $157 10 payments
  11. Other $1,180 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,914 391 payments
  2. Education $194 6 payments
Products named General payments · program years 2019–2025
  1. Ozempic $996 58 payments
  2. RYBELSUS $829 53 payments
  3. FARXIGA $761 51 payments
  4. FreeStyle Libre $487 28 payments
  5. DEXCOM G6 TRANSMITTER Endocrinology $396 13 payments
  6. Prolia $386 18 payments
  7. EVENITY $355 19 payments
  8. SOLIQUA 100/33 $347 20 payments
  9. TRULICITY $272 14 payments
  10. Dexcom G6 Transmitter Endocrinology $264 13 payments
  11. Other $3,722 227 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

397 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record